Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 4Unknown 2Terminated 2Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 11Gastrointestinal 11Thoracic 10Dermatologic 10Breast 6Head & Neck 5Gynecologic 5Sarcoma 4Other solid neoplasm 3CNS 3Tumor-Agnostic 2Lymphoid 2Endocrine 1

Conditions

Neoplasms 1Neoplasm Metastasis 1

Interventions

Gemcitabine 13pembrolizumab 12Capecitabine 9Irinotecan 8Erlotinib Hydrochloride 8Carboplatin 8Blood Specimen Collection 8Nivolumab 7Docetaxel 7Cisplatin 7Cetuximab 7Paclitaxel 6Everolimus 6130-nm albumin-bound paclitaxel 6vadimezan 5Magnetic Resonance Spectroscopy 5Fluorouracil 5Cyclophosphamide 5trametinib 4Leucovorin 4Lapatinib 4Ipilimumab 4Bevacizumab 4Albumin-Bound Paclitaxel 4temsirolimus 3atezolizumab 3abemaciclib 3Trastuzumab 3Radiotherapy 3Radiation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × spartalizumab × Tumor-Agnostic × Clear all
NCT02452268 2023-03-03

A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers

Novartis

Phase 1 Terminated
83 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT03351231 2020-08-26

An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer

Bristol-Myers Squibb

Phase 1/2 Terminated
7 enrolled 6 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡